Table 1 Characteristics of included studies
Study | Year | Age | Male% | Patients | Sample size | Treatment | Country |
|---|---|---|---|---|---|---|---|
Al Ali et al. [15] | 2016 | 57.9 (11.4) | 80.5 | CVD | 237 | MET | Netherlands |
Arturi et al. [16] | 2017 | 59.5 (9) | 70.0 | T2DM | 32 | GLP-1 agonist, DPP-4 inhibitor | Italy |
Bizino et al. [17] | 2019 | 60 (6) | 61.0 | T2DM | 49 | GLP-1 agonist | Netherlands |
Bonora et al. [18] | 2019 | 65.7 (5.9) | 66.7 | T2DM | 30 | SGLT-2 inhibitor | Italy |
Brenne et al. [19] | 2016 | 61.3 (11.0) | 79.3 | CVD | 173 | DPP-4 inhibitor | Austria |
Chen et al. [20] | 2017 | 66 (5) | 100.0 | T2DM + CVD | 23 | GLP-1 agonist | Netherlands |
Chen et al. [21] | 2016 | 58.0 (11.7) | 76.0 | T2DM + CVD | 90 | GLP-1 agonist | China |
Chen et al. [22] | 2015 | 57.7 (11.3) | 67.0 | T2DM + CVD | 92 | GLP-1 agonist | China |
Cohen et al. [23] | 2019 | 62.9 (6.8) | 58.8 | T2DM | 25 | SGLT-2 inhibitor | Australia |
Ghazzi et al. [24] | 1997 | 54 (10.8) | 54.0 | T2DM | 154 | TZDs, SU | USA |
Giles et al. [25] | 2008 | 64.2 (9.92) | 70.2 | T2DM + CVD | 518 | TZDs, SU | USA |
Halbirk et al. [26] | 2010 | 61 (3) | 86.7 | CVD | 15 | GLP-1 agonist | Denmark |
Hiramatsu et al. [27] | 2018 | 70.5 (5.7) | – | T2DM + CVD | 98 | GLP-1 agonist, DPP-4 inhibitor | Japan |
Hiramatsu et al. [28] | 2015 | 68.5 (9.4) | 86.7 | T2DM | 30 | GLP-1 agonist | Japan |
Jorgensen et al. [29] | 2017 | 57 (10) | Â | T2DM | 32 | GLP-1 agonist | Denmark |
Jorsal et al. [30] | 2017 | 65 (9.2) | 89.3 | T2DM + CVD | 241 | GLP-1 agonist | Denmark |
Kato et al. [12] | 2016 | 73.3 (6.6) | 60.0 | T2DM + CVD | 20 | DPP-4 inhibitor | Japan |
Kumarathurai et al. [31] | 2016 | 61.8 (7.6) | 79.0 | T2DM + CVD | 39 | GLP-1 agonist | Denmark |
Lambadiari et al. [32] | 2018 | 51 (12) | 66.7 | T2DM | 60 | GLP-1 agonist, MET | Greece |
Lepore et al. [33] | 2016 | 58 (10) | 74.0 | CVD | 56 | GLP-1 agonist | USA |
Leung et al. [34] | 2016 | 56 (6) | 56.0 | T2DM | 75 | DPP-4 inhibitor | Australia |
Lips et al. [35] | 2017 | – | – | T2DM + CVD | 38 | GLP-1 agonist | Czech Republic |
Liu et al. [36] | 2017 | 58 (15) | 53.3 | T2DM | 120 | GLP-1 agonist, MET | China |
Margulies et al. [37] | 2016 | 62 (52–68) | 80.0 | T2DM + CVD | 300 | GLP-1 agonist | USA |
Mcmurray et al. [38] | 2018 | 62.9 (8.5) | 77.3 | T2DM + CVD | 254 | DPP-4 inhibitor | UK |
Mohan et al. [39] | 2019 | 64.5 (8.9) | 84.0 | CVD | 63 | MET | UK |
Naka et al. [40] | 2010 | 64.3 (8.1) | 36.0 | T2DM + CVD | 81 | TZDs | Greece |
Nielsen et al. [41] | 2019 | 66 (7) | 94.4 | CVD | 36 | GLP-1 agonist | Denmark |
Nikolaidis et al. [42] | 2004 | 58 (3) | 70.0 | T2DM + CVD | 21 | GLP-1 agonist | USA |
Nogueira et al. [43] | 2014 | 57 (7) | 50 | T2DM | 29 | DPP-4 inhibitor | Brazil |
Nozue et al. [44] | 2016 | 68 (10) | 100.0 | T2DM + CVD | 15 | GLP-1 agonist | Japan |
Nystrom et al. [45] | 2017 | 61 (7.6) | 72.7 | T2DM + CVD | 62 | GLP-1 agonist, SU | Sweden |
Oe et al. [46] | 2015 | 67.8 (10.5) | 50.0 | T2DM + CVD | 80 | DPP-4 inhibitor | Japan |
Otagaki et al. [47] | 2019 | 70 (54–72) | 71.0 | T2DM | 42 | SGLT-2 inhibitor | Japan |
Ozawa et al. [48] | 2009 | 67.6 (8.8) | 75.0 | T2DM + CVD | 54 | TZD | Japan |
Sardu et al. [49] | 2018 | 72 (7) | 71.5 | T2DM + CVD | 559 | GLP-1 agonist | Italy |
Scognamiglio et al. [50] | 2002 | 61 (7) | 73.7 | T2DM + CVD | 38 | SU | Italy |
Sokos et al. [51] | 2006 | 61 (4) | 58.3 | T2DM + CVD | 21 | GLP-1 agonist | USA |
St John Sutton et al. [52] | 2002 | 56.1 (8.9) | 71.0 | T2DM | 203 | TZDs, SU | USA |
Türkmen Kemal et al. [53] | 2007 | 55.92 (8.26) | 23.1 | T2DM | 46 | TZD, MET | Turkey |
Van Der Meer et al. [54] | 2009 | 56.8 (1.0) | – | T2DM | 78 | TZD, MET | Netherlands |
Wägner et al. [10] | 2019 | 53.2 (9.7) | 41.7 | T2DM | 24 | GLP-1 agonist | Spain |
Wong et al. [55] | 2012 | 64 (8) | 90.0 | CVD | 61 | MET | UK |
Woo et al. [56] | 2013 | 59.5 (13.2) | 89.0 | CVD | 58 | GLP-1 agonist | Korea |
Yamada et al. [57] | 2017 | 69 (8) | 69.1 | T2DM | 115 | DPP-4 inhibitor | Japan |
Yamamoto et al. [58] | 2017 | 71 (10) | 62.0 | T2DM + CVD | 158 | DPP-4 inhibitor | Japan |
Yokoyama et al. [59] | 2007 | 63 (10) | 84.0 | T2DM + CVD | 93 | TZD | Japan |
Zhang et al. [60] | 2017 | 59.1 (11.8) | 77.0 | CVD | 52 | GLP-1 agonist | China |
Total studies [48] | Â | Â | Â | Â | 4790 | Â | Â |